Phase 3
Completed N=862
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Staphylococcal Skin Infection
Source: ClinicalTrials.gov NCT00091819 ↗
Enrolled (actual)
862
Serious AEs
6.8%
Results posted
Dec 2009
Primary outcomePrimary: Clinical Response — 323; 321; 52; 58 participants
Summary
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Response |
323; 321; 52; 58; 23; 16 | — |
Eligibility Criteria
Inclusion Criteria
- Patients must have a diagnosis of one of the following complicated skin and skin structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either suspected or confirmed as the major cause of the infection:
- major abscess requiring surgical incision and drainage
- infected burn (see exclusion criteria for important qualifications)
- deep/extensive cellulitis
- infected ulcer (see exclusion criteria for important qualifications)
- wound infections
- Patients must be expected to require at least 7 days of intravenous antibiotic treatment
Exclusion Criteria
- Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy prior to randomization
- Burns involving > 20% of body surface area or third-degree/full-thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fascitis, gas gangrene, or mediastinitis.
Data sourced from ClinicalTrials.gov (NCT00091819). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.